Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells

Published:2017-01-08 Issue:4 Volume:43 Page:628-636
ISSN:0363-9045
Container-title:Drug Development and Industrial Pharmacy
language:en
Short-container-title:Drug Development and Industrial Pharmacy

Author:

Karimzadeh Mahmonir¹,Rashidi Ladan²,Ganji Fariba³

Affiliation:

1. Chemical Engineering Department, Payam Noor University, Tehran, Iran;

2. Faculty of Food Industry and Agriculture, Standard Research Institute, Iranian National Standards Organization, Karaj, Iran;

3. Biotechnology Division, Faculty of Chemical Engineering, Tarbiat Modares University, Tehran, Iran

Publisher

Informa UK Limited

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03639045.2016.1275668

Reference24 articles.

1. A review of rivastigmine: A reversible cholinesterase inhibitor

2. Identification, characterization and quantification of new impurities by LC–ESI/MS/MS and LC–UV methods in rivastigmine tartrate active pharmaceutical ingredient

3. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation andex-vivocharacterization

4. Drug delivery through the blood-brain barrier

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Target to Alleviate Mitochondrial Dysfunctions in Alzheimer’s Disease: Recent Advances and Therapeutic Implications;Current Neuropharmacology;2024-10

2. Breaking Barriers in Alzheimer’s Disease: the Role of Advanced Drug Delivery Systems;AAPS PharmSciTech;2024-09-05

3. Recent developments in selective therapeutic targeting of functionalized nanomaterials to neurovascular units in overcoming the gaps in neurovascular therapy;Brain Disorders;2024-09

4. Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management;Journal of Controlled Release;2024-03

5. Nanoformulations targeting Alzheimer's disease;Alzheimer's Disease and Advanced Drug Delivery Strategies;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3